US 12,215,124 B2
Fluorinated nucleotides and uses thereof
Ronald Graham, Carlsbad, CA (US); Andrew Spaventa, La Jolla, CA (US); and Eli Glezer, Del Mar, CA (US)
Assigned to Singular Genomics Systems, Inc., San Diego, CA (US)
Appl. No. 16/969,879
Filed by SINGULAR GENOMICS SYSTEMS, INC., La Jolla, CA (US)
PCT Filed Feb. 20, 2019, PCT No. PCT/US2019/018810
§ 371(c)(1), (2) Date Aug. 13, 2020,
PCT Pub. No. WO2019/164977, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/633,505, filed on Feb. 21, 2018.
Prior Publication US 2022/0298201 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); C12Q 1/6869 (2018.01)
CPC C07H 21/04 (2013.01) [C12Q 1/6869 (2013.01); C12Q 2600/16 (2013.01)] 18 Claims
 
1. A nucleotide analogue having the formula:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein
B is a base or analogue thereof;
L2B, L2C, L2D, and L2E are independently a bond, —NN—, —NHC(O)—, —C(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, wherein at least one of L2A, L2B, L2C, L2D, and L2E is not a bond;
L4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R4 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R5 is a detectable label, an anchor moiety, or an affinity anchor moiety; and
X1 is hydrogen, halogen, —N3, or —CN.